EZH2 Inhibition Enhances the Activity of Carboplatin in Aggressive-Variant Prostate Cancer Cell Lines

Scientists studied the expression of polycomb repressive complex 2 genes in clinical prostate cancer cohorts. They determined the effect of enhancer of zeste homolog 2 (EZH2) inhibitor on cellular- and cell-free nucleosomal H3K27me3 levels.